Azenta, Inc.
Azenta (AZTA) held its Q3 2026 earnings call. CEO John Marotta said revenue exceeded outlook, profitability improved sequentially, and Multiomics grew year over year, with organic revenue up 9% YoY. The company revised FY2026 guidance to reported revenue of $613M to $618M and adjusted EBITDA of $59M to $62M, citing uneven demand and turnaround progress.
Azenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. azta-20260810 0000933974 FALSE 0000933974 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):
Conestoga Capital Advisors’ Q2 2026 investor letter highlighted a shift toward small caps, citing Russell 2000 and Russell 2000 Growth gains, while noting uneven leadership hurt quality-focused strategies. The firm said it sold Azenta, Inc. (NASDAQ:AZTA) after execution issues, weaker life sciences funding, and softer capital equipment demand led management to lower its full-year outlook. Azenta closed Aug. 5 at $31.82.
Over the past 7 days, alphai's AI scored 2 news stories mentioning AZTA (Azenta, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent AZTA coverage spans earnings, financial news and corporate actions.
In the last 30 days, AZTA insiders filed 1 SEC Form 4 transaction — 1 purchase ($8K) and no sales. The most active reporter was Starr Ephraim, SVP, Gen Counsel & Secretary, with 1 filing.
The call provides a fresh FY2026 outlook range plus operational updates (Multiomics turnaround, automated store remediation, AI-enabled biorepository deployment) that can drive near-term estimate revisions.
This is a governance and finance-ops change, not a direct earnings or guidance update, but it can affect near-term accounting oversight and internal controls.
The article is a hedge-fund letter citing a deteriorating demand backdrop and a reduced full-year outlook, plus Conestoga’s decision to exit.
This is a routine insider open-market purchase with no stated 10b5-1 plan, but it does not by itself signal a new fundamental catalyst.
The article discloses a Q2 beat on both revenue and adjusted EPS, plus a stated full-year EPS growth expectation, which can support near-term sentiment but leaves margin and longer-term growth concerns.
alphai scores every news story that mentions AZTA with an AI model for sentiment and relevance, and aggregates insider trades from Azenta, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Azenta (AZTA) held its Q3 2026 earnings call. CEO John Marotta said revenue exceeded outlook, profitability improved sequentially, and Multiomics grew year over year, with organic revenue up 9% YoY. The company revised FY2026 guidance to reported revenue of $613M to $618M and adjusted EBITDA of $59M to $62M, citing uneven demand and turnaround progress.
7 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. azta-20260810 0000933974 FALSE 0000933974 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported):
2 min readConestoga Capital Advisors’ Q2 2026 investor letter highlighted a shift toward small caps, citing Russell 2000 and Russell 2000 Growth gains, while noting uneven leadership hurt quality-focused strategies. The firm said it sold Azenta, Inc. (NASDAQ:AZTA) after execution issues, weaker life sciences funding, and softer capital equipment demand led management to lower its full-year outlook. Azenta closed Aug. 5 at $31.82.
4 min readStarr Ephraim (SVP, Gen Counsel & Secretary) purchased 335 shares of Azenta, Inc. (AZTA) at $24.17 on 2026-07-31.
1 min readAzenta (NASDAQ:AZTA) reported Q2 CY2026 results. Revenue rose 12% year on year to $161.2 million, exceeding Wall Street estimates by 8%, and non-GAAP EPS was $0.16, 60% above consensus and down from $0.19 a year earlier. Analysts expect full-year EPS to rise from $0.42 to $0.64 over the next 12 months.
4 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 azta-2026q326erxexx991.htm EX-99.1 Document Exhibit 99.1 Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026. BURLINGTON, Mass., August 4, 2026 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended
6 min readAzenta (NASDAQ:AZTA) will report Q2 results Tuesday after the bell. The company missed prior-quarter revenue and EPS expectations, with revenue at $144.8 million, flat year on year. For Q2, analysts expect revenue up 3.7% y/y. The stock is up 9.6% over the past month, with an average price target of $27.80 versus $28.13.
3 min readAzenta, Inc. (AZTA) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-10.1 3 exhibit101-xexxazentaxthel.htm EX-10.1 Document Execution version Vendor loan agreement between Thelema as Borrower and Azenta Germany GmbH as Lender 1 July 2026 In accordance with Item 601(a)(6) of Regulation S-K, private information has been redacted as indicted in th
3 min readThe article compares Q1 results across life-sciences tools stocks. West Pharmaceutical Services posted the biggest analyst estimate beat; its shares were up 18% to $323.85. Azenta reported $144.8M revenue (+1% YoY), missing expectations by 2.5%, and shares fell 5.8% to $23.19. Bruker revenue was $823.4M (+2.7%), beating by 3.4%, shares up 56% to $59.30. Illumina revenue was $1.09B (+4.8%), beating by 1.8%, shares up 29.1% to $163.68.
6 min readPomerantz LLP is investigating potential securities fraud claims against Azenta, Inc. (AZTA) on behalf of investors. This comes after Azenta reported lower-than-expected Q2 2026 financial results, including a $149 million goodwill impairment charge and reduced its full-year fiscal 2026 outlook. Following this news, Azenta's stock price dropped by over 25%.
3 min read
